Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Assistance Publique - Hôpitaux de Paris
With
URC-CIC Paris Descartes Necker Cochin
ANAD is not a rare type of hearing loss. Nevertheless, its profile is heterogeneous and the pathology remain underdiagnosed. The investigators will screen all new patients with bilateral severe to profound HL, looking for DFNB9. They will analyse their electrophysiology (auditory potential, and otoacoustic emission), and their audio-vestibular profile, at an early stage and one year after inclusion. All patients will be seen in the genetic clinic. Also, the investigators will analyse all patients with ANAD profile and patients known with ANAD.
All informations will provide precise data base to allow a better understanding of the pathology. It might also lead to select the best candidates for future gene therapy
Age
0–25
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Child from 0 to 3 years old
Child with severe to profound bilateral deafness newly diagnosed with:
Average hearing threshold\> 70 decibel on each ear
and / or no response to 70 decibel PEA on each ear
and / or no response to ASSR
Child under 16
Child with newly diagnosed hearing neuropathy : tonal/vocal dissociation (when this is possible), and/or modified PEA, and/or discordant ASSR, and/or OEA present.
Adult patient under 25 or child
Patient with deafness with auditory neuropathy
Patient known to have 1 or 2 mutations of the otoferlin protein
You may not be if
Other type of deafness such as : unilateral deafness, deafness of transmission, malformation syndrome, known genetic familial deafness not DFNB9
Patient without medical insurance
Lack of consent to DNA sampling, of one or both biological parents (consent of the care)